Vasodilation of retinal arterioles induced by activation of BKCa channels is attenuated in diabetic rats
Related Experiment Video
Updated: May 29, 2026

Isolation of Retinal Arterioles for Ex Vivo Cell Physiology Studies
Published on: July 14, 2018
Asami Mori1, Sachi Suzuki, Kenji Sakamoto
1Department of Molecular Pharmacology, Kitasato University School of Pharmaceutical Sciences, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan.
Abstract:
The large-conductance Ca(2+)-activated K(+) (BK(Ca)) channels modulate the retinal vascular tone, but question of whether the impairment of the channel function contributes to abnormalities of retinal circulation has not yet been completely elucidated. The purpose of this study was to examine effects of diabetes on the vasodilation induced by activation of BK(Ca) channels. Male Wistar rats were treated with streptozotocin and experiments were performed 2 weeks later. The streptozotocin-treated animals were given drinking water containing 5% d-glucose to shorten the term in the development of retinal vascular dysfunction. The retinal vascular responses were assessed by measuring diameter of retinal arterioles in the fundus images that were captured with an original fundus camera system. In non-diabetic rats, vasodilator effects of acetylcholine on retinal arterioles were significantly reduced by iberiotoxin, an inhibitor of BK(Ca) channels. However, the inhibitory effect of iberiotoxin was not observed in diabetic rats, and the responses to the BK(Ca) channel opener BMS-191011 were almost completely abolished. The retinal vasodilator response to acetylcholine, possibly an endothelium-derived hyperpolarizing factor-mediated response, observed after treatment with N(G)-nitro-l-arginine methyl ester and indomethacin was markedly reduced in diabetic rats. The responses to pinacidil, an opener of ATP-sensitive K(+) channels, were unchanged. These results suggest that the retinal vasodilator response mediated through mechanisms involving activation of BK(Ca) channels is diminished at the early stage of diabetes in rats. The impairment of BK(Ca) channel function may contribute to abnormal retinal hemodynamics in diabetes and consequently play an important role in the pathogenesis of diabetic retinopathy.
Insights
Diabetes impairs large-conductance Ca(2+)-activated K(+) (BK(Ca)) channels, diminishing retinal vasodilation. This BK(Ca) channel dysfunction may contribute to abnormal retinal circulation and diabetic retinopathy.
Area of Science:
- Ophthalmology
- Cardiovascular Research
- Endocrinology
Background:
- Large-conductance Ca(2+)-activated K(+) (BK(Ca)) channels regulate retinal vascular tone.
- The role of BK(Ca) channel impairment in retinal circulation abnormalities, particularly in diabetes, requires further elucidation.
Purpose of the Study:
- To investigate the impact of diabetes on BK(Ca) channel-mediated vasodilation in the retina.
- To assess early-stage diabetic effects on retinal vascular function.
Main Methods:
- Male Wistar rats were induced with diabetes using streptozotocin and supplemented with glucose.
- Retinal arteriolar responses were measured using fundus imaging.
- Pharmacological agents, including BK(Ca) channel inhibitors (iberiotoxin) and openers (BMS-191011), were used to assess channel function.
Main Results:
- Iberiotoxin inhibited acetylcholine-induced vasodilation in non-diabetic rats but not in diabetic rats.
- Responses to the BK(Ca) channel opener BMS-191011 were abolished in diabetic rats.
- Vasodilator responses mediated by BK(Ca) channels were significantly reduced in early-stage diabetes.
Conclusions:
- Early-stage diabetes in rats diminishes retinal vasodilator responses involving BK(Ca) channel activation.
- Impaired BK(Ca) channel function may contribute to aberrant retinal hemodynamics in diabetes.
- BK(Ca) channel dysfunction is implicated in the pathogenesis of diabetic retinopathy.
Related Concept Videos
Diabetic Retinopathy
Diabetic Nephropathy
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Action of Calcium Channel Blockers
Antihypertensive Drugs: Vasodilators

